Ann Aerts – Head, Novartis Foundation, Switzerland
Dr Ann Aerts, head of the Novartis Foundation, discusses the role the Novartis Foundation plays within low and middle- income countries across the world and how integrating digital health solutions…
Understanding the mechanisms of disease
The Friedrich Miescher Institute is devoted to fundamental biomedical research aimed at understanding the basic molecular mechanisms of health and disease. We communicate and patent our findings to enable their translation into medical application.
The FMI focuses on the fields of
» Epigenetics
» Quantitative Biology
» Neurobiology
In these fields, the FMI has gained international recognition as a center of excellence in innovative biomedical research.
Training young scientists
The Friedrich Miescher Institute contributes to the training of graduate students and postdoctoral fellows. Through its PhD program, which was established as early as 1970, the FMI attracts top international students. The FMI is affiliated with the University of Basel, where most of the graduate students are enrolled and where it contributes to the teaching program. Many FMI alumni have gone on to pursue successful careers in Novartis, in other pharmaceutical companies, or in academic research.
Contact
Friedrich Miescher Institute for Biomedical Research
Maulbeerstrasse 66
4058 Basel
Switzerland
Tel.: +41 61 697 66 51
Dr Ann Aerts, head of the Novartis Foundation, discusses the role the Novartis Foundation plays within low and middle- income countries across the world and how integrating digital health solutions…
Lukas Engelberger discusses the challenges and benefits of the healthcare system in Switzerland and the Canton of Basel-Stadt, new milestones in dentistry and the organizational structure between the hospitals and…
Carolin Hillebrand, country manager of Neurim Pharmaceuticals Switzerland, a neuroscience specialty company, discusses the launch of their lead product Circadin, the only IP-protected product providing a prolonged release formulation of…
CEO of Biomed, Dr. Thomas F. Szuran discusses the keys to success for pharma SMEs and the importance of relationship management, investments, and a culture of internal dialogue. Could you…
Walter Steinlin describes the Federal Commission of Technology and Innovation as a catalyst for turning research into innovation. Based in Bern, Switzerland, the commission funds research institutes in corporate projects,…
Jean-Daniel Gerber, chairman of the board at SIFEM, explains why job creation should be the focus of DFIs (Development Finance Institutions) such as SIFEM; how ESG, environmental, social and governance…
Ronald Scott, CEO of Basilea, a biotech company that was spun out of Roche in 2000, talks about launching its first two products, Zevtera and Cresemba; the milestone agreement with…
Actelion’s global CEO and co-founder, Dr Jean-Paul Clozel, discusses diversifying the company’s portfolio, prioritizing internal research over inorganic acquisitions, and retaining a spirit of independence and innovation during a period…
André Lüscher of Gilead Switzerland, reveals how the case of Sovaldi demonstrates the challenges for a healthcare system to handle a truly disruptive medical innovation, the knock-on effect on Gilead´s…
Andreas Bosshard of Mepha-Teva in Switzerland describes Switzerland’s unique generics market, the quality of the Mepha-Teva brand, innovations within generics, and the company’s growth strategy within the Swiss market. It…
Franz Saladin details the unique scope and operations of the Basel Chamber of Commerce, the history of pharmaceuticals in Basel, and the importance of continuously developing the industry within the…
Biologics giant Biogen is investing USD one billion in a next-generation manufacturing facility in Luterbach, near Solothurn, Switzerland, tripling production capacity and creating 400 new jobs. The decision to situate…
See our Cookie Privacy Policy Here
